Skip Navigation
Skip to contents

Clin Endosc : Clinical Endoscopy

OPEN ACCESS

Articles

Page Path
HOME > Clin Endosc > Ahead-of print articles > Article
Review Endoscopic anti-reflux treatment for gastroesophageal reflux disease
Chu-Kuang Chou1,2orcid, Chien-Chuan Chen3orcid, Ping-Huei Tseng3,4orcid

DOI: https://doi.org/10.5946/ce.2026.007
Published online: May 19, 2026

1Division of Gastroenterology and Hepatology, Department of Internal Medicine, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi, Taiwan

2Obesity Center, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi, Taiwan

3Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

4Division of Endoscopy, Department of Integrated Diagnostics and Therapeutics, National Taiwan University Hospital, Taipei, Taiwan

Correspondence: Ping-Huei Tseng Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 110225, Taiwan E-mail: pinghuei@ntu.edu.tw
• Received: December 31, 2025   • Revised: February 23, 2026   • Accepted: February 26, 2026

© 2026 Korean Society of Gastrointestinal Endoscopy

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 5,893 Views
  • 339 Download
  • Gastroesophageal reflux disease (GERD) is a heterogeneous condition with substantial diagnostic and therapeutic complexities. Endoscopic anti-reflux therapies have emerged as minimally invasive options positioned between pharmacological therapy and surgical fundoplication. However, their optimal role remains incompletely defined. Endoscopic anti-reflux therapies encompass distinct mechanistic categories, including mucosal remodeling–based interventions, neuromodulatory therapy, and endoscopic fundoplication. Among these, transoral incisionless fundoplication has the most clearly defined role in current international guidelines for carefully selected patients with mild-to-moderate GERD, predominant regurgitation, and minimal anatomical disruption. In contrast, radiofrequency-based therapy is generally confined to a limited symptom-oriented role. Anti-reflux mucosal interventions represent an evolving approach with encouraging results from observational studies and meta-analyses; however, their use remains limited by the heterogeneity of techniques and lack of robust randomized evidence. This review provides an evidence-based appraisal of contemporary endoscopic anti-reflux therapies, focusing on the mechanistic rationale, patient selection, clinical outcomes, and guideline positioning. Accurate diagnosis and phenotypic classification are essential. Objective confirmation of pathological reflux, assessment of the esophagogastric junction anatomy, and evaluation of esophageal motility are critical for distinguishing patients who may benefit from endoscopic intervention from those with functional or overlapping esophageal disorders.
Gastroesophageal reflux disease (GERD) is a chronic digestive disorder affecting millions of people worldwide. It occurs when stomach acid or bile flows back into the esophagus, causing irritation and symptoms such as heartburn, regurgitation, and difficulty swallowing. GERD can significantly affect the quality of life and may lead to complications such as esophagitis, strictures, and Barrett's esophagus. GERD has become a significant socioeconomic burden worldwide, including in Asia.1,2
Although lifestyle modifications and pharmacological treatments are often effective in managing mild-to-moderate GERD, these approaches may not adequately relieve symptoms in all patients. Up to 40% of patients with GERD continue to experience symptoms despite being on proton pump inhibitor (PPI) therapy.3 Traditional anti-reflux surgical options, such as Nissen fundoplication, involve wrapping the top part of the stomach around the lower esophagus to reinforce the lower esophageal sphincter. Although effective, these surgical procedures are invasive, with higher risks and longer recovery times, and can lead to complications such as postoperative dysphagia, gas bloat syndrome, and inability to vomit/belch.4-6 The efficacy of Nissen fundoplication also declines over time, including increased PPI usage for recurrent symptoms and an increased reoperation rate reaching a combined 39.6% after 10 years.6
Endoscopic anti-reflux treatments offer a minimally invasive alternative, providing symptom relief with fewer complications and quicker recovery. These procedures aim to enhance the function of the lower esophageal sphincter (LES) or reduce reflux through various techniques, such as radiofrequency therapy, endoscopic fundoplication, and endoscopic suturing.7 As technological advancements continue, endoscopic treatments are becoming more refined and accessible, presenting a viable option for patients who are not candidates for traditional surgery or who prefer less invasive approaches.7
Importantly, the optimal role of endoscopic anti-reflux therapy cannot be defined in isolation. The contemporary management of GERD increasingly requires a multidisciplinary approach involving primary care providers, gastroenterologists with expertise in esophageal motility disorders, and surgeons to ensure accurate diagnosis, appropriate patient selection, and longitudinal follow-up. At present, however, the clinical roles of most endoscopic anti-reflux interventions have not been validated by large, well-designed, randomized controlled trials (RCTs) incorporating rigorous patient phenotyping and sham controls.
The marked heterogeneity of GERD, challenges in phenotypic classification, and frequent overlap with functional esophageal disorders substantially limit the reproducibility and generalizability of the reported outcomes. Advances in pharmacological therapy have raised the benchmark for symptom control, making it increasingly difficult to define the incremental benefits attributable to endoscopic intervention alone. Moreover, robust evidence of its long-term durability and cost-effectiveness is limited.
Importantly, current endoscopic anti-reflux therapies have not been shown to improve hard clinical endpoints. There is no evidence of an association between improved survival and a protective effect against the development of Barrett’s esophagus or esophageal adenocarcinoma. Most studies have focused primarily on symptom relief, health-related quality of life, and reduction in acid-suppressive medication use. The impact on broader health outcomes, such as disability-adjusted life years, has rarely been evaluated, further complicating the assessment of cost-effectiveness compared with long-term pharmacologic therapy or surgical anti-reflux interventions. Collectively, these limitations underscore the need for a cautious, evidence-based appraisal of endoscopic anti-reflux therapies within the broader context of contemporary GERD management.
GERD arises from dysfunction of the esophagogastric junction (EGJ), a complex anti-reflux barrier composed of the LES, crural diaphragm, and gastroesophageal flap valve (GEFV). Reflux occurs when the integrity or coordination of these components is compromised, allowing gastric contents to enter the esophagus. Key pathophysiologic mechanisms include transient LES relaxation, reduced basal LES pressure, disruption of the GEFV, and the presence of a hiatal hernia, often accompanied by impaired esophageal clearance and delayed gastric emptying.7 Importantly, most endoscopic anti-reflux therapies primarily target the intraluminal or mucosal components of the anti-reflux barrier, with limited ability to correct extrinsic factors such as crural diaphragmatic dysfunction or large hiatal hernia. These fundamental mechanistic constraints underscore the importance of understanding the GERD pathophysiology when considering endoscopic interventions and provide a basis for careful patient selection.
Accurate diagnosis is a prerequisite for endoscopic anti-reflux therapy. Symptom-based diagnoses alone are insufficient, particularly in patients with refractory or atypical symptoms. Contemporary diagnostic frameworks emphasize the need for objective evidence of pathological reflux before invasive interventions. The updated Lyon Consensus 2.0 provides a structured approach for defining actionable GERD using endoscopic findings, high-resolution manometry (HRM), and ambulatory reflux monitoring performed on or off antisecretory therapy. Conclusive evidence of GERD includes advanced erosive esophagitis (Los Angeles classification grades B–D), biopsy-proven Barrett’s esophagus, peptic stricture, or abnormal esophageal acid exposure time (AET), defined as >6% on pH-impedance monitoring or at least 2 days of wireless pH monitoring. In contrast, borderline findings, such as Los Angeles classification grade A esophagitis, AET between 4% and 6%, or intermediate numbers of reflux episodes, are considered inconclusive and require supportive evidence from adjunctive testing.8 In Asian populations, several studies suggest that lower AET thresholds may better reflect clinically relevant reflux, and abnormal acid exposure has been proposed at values exceeding 4%.9,10 Nonetheless, in the absence of unequivocal objective evidence, invasive therapies—including endoscopic interventions—should be approached with caution.9,10
The diagnosis of refractory GERD requires a complex workup. GERD should be proven and differentiated from functional heartburn or reflux hypersensitivity using esophageal functional testing. If the symptoms persist under PPI therapy for proven GERD, further evaluation with on-PPI pH-impedance monitoring or endoscopy is suggested to differentiate overlapping functional disorders from proven or true refractory GERD.3,8
The first-line treatment for refractory GERD is diet and lifestyle interventions. This includes weight reduction, avoiding eating dinner close to bedtime, and adopting postural measures such as elevating the head by at least 20 cm or in the left lateral position.3 For refractory GERD with lifestyle intervention failure, optimizing acid-suppressive therapy should be confirmed with drug compliance and a trial of double-dose PPI. Adjunctive medications can also be considered. When non-invasive interventions have failed, invasive interventions may be considered.11
Endoscopic treatment for GERD is a minimally invasive procedure aimed at improving the function of the LES or GEFV to reduce the reflux burden through various mechanical or ablative techniques. These procedures offer a viable alternative for patients who do not respond adequately to medical therapy or who prefer to avoid more invasive surgical options.
It is crucial to identify the presence of major esophageal motility disorders before endoscopic intervention. Currently, HRM is the gold standard for evaluating esophageal motility and diagnosing disorders such as achalasia, distal esophageal spasm, and ineffective esophageal motility, which may require different therapeutic approaches.12 The integrity of the GEFV is a critical factor in preventing reflux. Endoscopic assessment and grading of the GEFV can provide valuable information on the likelihood of successful treatment. The Hill classification system is commonly used to grade GEFV, with grades I and II indicating a normal or mildly compromised valve, and grades III and IV indicating a significantly compromised valve, often associated with hiatal hernia.13 Presence of erosive esophagitis, Barrett’s esophagus, and hiatal hernia should be evaluated using upper endoscopy. The Los Angeles classification system grades erosive esophagitis from A to D based on the extent and severity of the mucosal breaks. The decision-making process regarding PPI discontinuation is different for patients with Barrett’s esophagus after anti-reflux endoscopic therapy than for those without Barrett’s esophagus. In summary, a comprehensive evaluation, including diagnosis of GERD, assessment of esophageal motility, evaluation of GEFV, and assessment of erosive esophagitis and related complications, is essential prior to endoscopic treatment. Such a thorough diagnostic approach ensures that patients are appropriately selected for endoscopic procedures, thereby optimizing the chances of treatment success and minimizing the risk of complications.
Among the various endoscopic anti-reflux procedures, one group focuses on mucosal remodeling of the EGJ, inducing tissue contraction and fibrosis to reinforce the GEFV and reduce junctional compliance. Another category includes approaches to altering the LES function through energy-based delivery. The third group consists of endoluminal fundoplication- or plication-based procedures that attempt to recreate the anatomical configuration of the anti-reflux barrier. Emerging hybrid techniques continue to be developed, although supporting clinical evidence remains limited (Table 1).
Anti-reflux mucosal interventions (ARMI) can be used to reconstruct the GEFV by scarring and tightening the cardia and EGJ. Anti-reflux mucosectomy (ARMS), anti-reflux mucosal ablation (ARMA), and anti-reflux band ligation (ARBL) are three major procedure types.14-16 Compared to other endoscopic management techniques, these methods require no expensive instruments and have acceptable procedure times. ARMI has gained popularity in recent years owing to increasing evidence of its effectiveness in PPI-refractory or PPI-dependent GERD.
Yeh et al.14 reported in a meta-analysis that the combined clinical success rate was 73.8% (95% confidence interval [CI], 69%–78%) overall, with specific rates of 68.6% (95% CI, 62.2%–74.4%) for ARMS, 86.7% (95% CI, 78.7%–91.9%) for ARMA, and 76.5% (95% CI, 65%–85.1%) for ARBL. ARMI significantly improved the severity of acid exposure, DeMeester score, and hiatal hernia. Approximately 10% of the patients required endoscopic dilatation due to dysphagia following ARMS or ARMA, while ARMS had a perforation rate of 2.2%. In contrast, no incidents of bleeding, perforation, or severe dysphagia were observed with ARBL. Our clinical data on ARMI in Taiwan showed that 73.9% of patients reported subjective improvement. AET decreased significantly from 4.6 to 2.1 (p=0.013), and 56.5% discontinued PPIs. However, a negative effect with worsening reflux was also observed in 13% of the study participants.17 These findings underscore ARMI’s efficacy and safety in PPI-dependent GERD, while careful post-treatment monitoring could not be overemphasized.
The concept of ARMS was first proposed by Inoue et al. in 2014.18 Initially, ARMS utilized the endoscopic submucosal dissection technique, which is time-consuming and technically challenging. However, the procedure has evolved to primarily use endoscopic mucosal resection (EMR) or band ligation followed by EMR, simplifying the process and improving efficiency.19-21 The long-term efficacy of ARMS in treating GERD has initially been questioned. Sumi et al.15 presented a single-center prospective study of 88 patients treated between June 2012 and June 2017 with a 5-year follow-up. The results showed long-term symptom relief in 68.3% of patients and PPI discontinuation in 42%. Additional treatments were necessary for 23% of patients within 1–2 years post-procedure.22 ARMS also demonstrated effectiveness in treating patients with extraesophageal GERD, also known as laryngopharyngeal reflux disease, in the context of careful patient selection.23 In a prospective single-center cohort of 96 patients undergoing cap-assisted ARMS, symptom scores of GERD questionnaire (GERDQ) improved significantly from 10.67 to 7.55 (p<0.001), with symptom improvement observed in 86% of patients and 36 patients able to reduce or discontinue PPI use, with clinical outcomes assessed at 6 months and extended follow-up beyond 2 years in a subset of patients.24
This retrospective single-center study compared 36 patients who underwent ARMS with 96 patients who underwent Stretta radiofrequency therapy. Both groups demonstrated comparable rates of symptom improvement and PPI withdrawal (61.1% vs. 59.4%); however, ARMS was associated with significantly greater improvements in endoscopic esophagitis, GEFV grade, distensibility index on a functional luminal imaging probe (EndoFLIP; Medtronic), and resolution of Barrett’s esophagus.25 These findings were further supported by a multicenter Korean retrospective cohort that included 164 patients treated with ARMS and 213 patients treated with Stretta. Although symptom relief and PPI discontinuation rates remained similar between the groups (86.0% vs. 85.4%), ARMS consistently demonstrated superior improvements in objective endoscopic and functional parameters, including flap valve grade, Los Angeles classification, EndoFLIP distensibility index, and Barrett’s esophagus resolution.26
Anti-reflux mucoplasty, ARMS with valve creation, and ARM-P have been proposed as investigational modifications of ARMS procedures, incorporating mucosal resection and immediate defect closure to promote more rapid and controlled remodeling of the EGJ, to enhance anti-reflux efficacy, reduce procedure-related adverse events, and create a neo–GEFV to augment the anti-reflux barrier.27-29 In a retrospective single-center study of 20 patients with PPI-refractory/dependent GERD, ARM-P achieved 100% technical success without adverse events. Symptom scores and Hill’s grades significantly improved, with 55% discontinuing PPI use and 15% reducing the PPI dose by half.28
ARMA involves ablation of the mucosa to induce shrinking scarring, thereby reconstructing the EGJ barrier. In comparison to ARMS, ARMA is less technically demanding and may have fewer complications.14,30 Chavan et al.31 conducted a randomized, sham-controlled trial investigating the efficacy of ARMA in patients with “reflux-predominant” refractory GERD. This study specifically targeted patients with high reflux episodes (>80) despite optimized PPI therapy. At the 6-month follow-up, 71.4% of the ARMA group achieved a ≥50% improvement in GERD health-related quality of life (GERD-HRQL) scores, compared to only 3.6% in the sham group (p<0.001). Furthermore, the ARMA group showed significant physiological improvements, including reduced AET, a decrease in non-acid reflux episodes, and improved endoscopic Hill’s grade, with 35.7% of patients successfully discontinuing PPI therapy entirely. In another international bi-center study with prospectively collected data, a total of 68 patients underwent ARMA for GERD refractory to or dependent on acid-suppressive therapy. Symptomatic improvement was achieved in approximately 60% of the patients at 2–6 months and 70% at 12 months after the procedure. Among the 51 patients (71.8%) who underwent postprocedural 24-hour pH monitoring, the median esophageal AET decreased significantly from 5.3% to 0.7%, accompanied by a significant reduction in endoscopic esophagitis rates. Notably, both patients with objectively confirmed GERD (64.7%) and those with reflux hypersensitivity (35.3%) showed symptomatic benefits. With respect to safety, transient postprocedural stenosis occurred in nine patients (13.2%), all of whom were successfully managed with endoscopic balloon dilation.32 The long-term efficacy of ARMA was demonstrated in a study of 108 patients with refractory GERD. The AET and prevalence of esophagitis remained low, and 78% of the patients were off PPI after a 3-year follow-up.33
Notably, the effects of ARMA extend beyond EGJ reinforcement. In a prospective physiological study, our group demonstrated that this intervention was associated not only with improvement in reflux symptoms and reflux burden but also with enhancement of EGJ barrier function and esophageal body contractility, as assessed using high-resolution impedance manometry 3 months after treatment in patients with PPI-dependent GERD. These findings suggest a broader functional impact of ARMI on esophageal motor performance beyond localized junctional remodeling.34
A multicenter retrospective study comparing the performance of ARMS (n=164) and ARMA (n=84) in patients with refractory GERD demonstrated that ARMS yields better clinical and endoscopic outcomes. Specifically, ARMS achieved a significantly greater median reduction in GERDQ scores (4.0 vs. 2.0, p=0.002) and higher rates of PPI withdrawal (61.4% vs. 40.3%, p=0.008) compared to those with ARMA. Furthermore, ARMS was more effective in improving reflux esophagitis (56.7% vs. 26.2%, p<0.001) and flap valve grades (71.3% vs. 36.9%, p<0.001). However, ARMA demonstrated a superior safety profile regarding postprocedural bleeding (6.0% vs. 15.2%, p=0.034), whereas both procedures had comparable stricture rates (8.3% vs. 8.5%, p=0.957).30
However, the role of ARMI has not been well-defined or endorsed by most major international GERD guidelines.1,3 (Table 2) The 2020 European Society of Gastrointestinal Endoscopy (ESGE) guidelines suggest against routine ARMS use owing to limited data and potential risks.35 More well-designed RCTs with a sham-control arm are needed to confirm its short-term and long-term effects and to better define the specific roles of ARMI across different GERD phenotypes.
The Stretta procedure (Mederi Therapeutics) applies radiofrequency energy to the LES and gastric cardia to induce submucosal fibrosis and potentially increase the LES pressure. It involves a single radiofrequency balloon catheter with four nitinol needle electrodes, delivering energy with an overall procedure time of around 1 hour. This method is suitable for patients without a hiatal hernia or severe anatomical distortions.36 Clinical evidence from RCTs and systematic reviews regarding Stretta's ability to normalize acid exposure or LES pressure remains inconsistent.37,38 Short-term studies suggest improvements in symptom burden and quality of life, although long-term data are limited. Meta-analyses have shown mixed results: one indicated symptom and acid exposure improvements, while another found no significant differences compared to sham therapy or PPIs.7,39,40 In a multicenter double-blind, sham-controlled randomized trial for patients with PPI-refractory heartburn in eight French centers, esophageal radiofrequency energy delivery with the Stretta procedure did not demonstrate any better efficacy in terms of symptom relief or PPI consumption compared to the sham procedure.41
Recommendations for the Stretta procedure also vary among the major guidelines. The 2020 ESGE guidelines recommend considering Stretta in selected patients for symptom relief, provided erosive esophagitis and hiatal hernia are absent.35 The 2022 consensus from multiple surgical (including thoracic and bariatric) and endoscopy societies acknowledges that Stretta may offer symptomatic benefits compared to that with medical therapy in selected patients. Nevertheless, surgical fundoplication remains the preferred option when feasible. Stretta is suggested only for patients who decline surgery or are poor surgical candidates, with the panel highlighting the lack of durable objective reflux control and the low certainty of available evidence.37 The 2022 American College of Gastroenterology (ACG) Clinical Guideline cannot recommend its use as an alternative to medical or surgical anti-reflux therapies, citing its inconsistent efficacy, highly variable outcomes, and limited objective improvement in reflux parameters, with the overall certainty of evidence graded as low.1 The AGA, in its 2022 clinical practice update on personalized GERD management, does not include Stretta among recommended therapeutic options. Instead, the AGA emphasizes optimization of pharmacologic therapy and, when invasive intervention is required, favors laparoscopic fundoplication or selected endoscopic fundoplication techniques, implicitly reflecting the absence of sufficient evidence to support Stretta in routine clinical practice.38 The American Society for Gastrointestinal Endoscopy (ASGE), in its 2025 guideline update, positions Stretta as a fallback option. ASGE suggests that Stretta may be considered only when standard surgical or endoscopic fundoplication is not feasible or available, and only in patients with objectively confirmed GERD, minimal hiatal hernia (≤2 cm), and preserved gastroesophageal valve anatomy. This recommendation is conditional and based on low-quality evidence, underscoring substantial uncertainty regarding long-term efficacy (Table 2).36
Transoral incisionless fundoplication (TIF) is an endoscopic procedure that uses the EsophyX device (EndoGastric Solutions) to recreate the GEFV through full-thickness plications. TIF involves folding the gastric fundus around the distal esophagus and securing it with polypropylene T-fasteners. This procedure tightens the sling fibers, steepens the angle of His, and enhances the cardiac notch to restore the flap valve mechanism. Ideal candidates for TIF typically have no or a small hiatal hernia (<2 cm) and a Hill valve grade of 1 or 2. In 2007, the U.S. Food and Drug Administration approved TIF for GERD treatment.
TIF has been studied in several RCTs, primarily in moderate GERD cases, excluding severe esophagitis or Barrett's esophagus.42 Meta-analyses indicate that TIF achieves a clinical response (≥50% improvement in GERD-HRQL or symptom remission) in 66% of patients compared to 30% in the control groups. However, objective measures showed only a limited decrease in AET, similar to PPI therapy. A recent systematic review and meta-analysis of TIF for refractory GERD (32 studies, 1,475 patients) found that TIF significantly improved symptoms, and 89% of patients could discontinue PPI.43 Another systematic review and meta-analysis of TIF (8 studies, 418 patients) showed high patient satisfaction rates, with nearly 75% of patients able to reduce or discontinue PPI.44 Long-term follow-up from uncontrolled studies suggests decreasing effectiveness over time, with PPI cessation rates ranging from 70% at 6 months to 34% at 5 years.42 Adverse events, including esophageal perforation and bleeding, occurred in 2.4% of patients.35
The ACG, in its 2022 guidelines, recognizes TIF as a potential therapeutic option for carefully selected patients with proven GERD, particularly those with persistent regurgitation despite optimized PPI therapy, provided that no hiatal hernia greater than 2 cm and no severe erosive esophagitis are present. The recommendation is conditional and based on low-quality evidence, reflecting modest but consistent improvements in symptom control and regurgitation.1 The AGA, in its 2022 clinical practice update on personalized GERD management, similarly positions TIF as the only endoscopic anti-reflux procedure with sufficient evidence to be considered in routine practice. The AGA emphasizes that TIF should be reserved for patients with objective evidence of reflux, minimal anatomical disruption of the EGJ, and a clear predominance of regurgitation symptoms, while reiterating that surgical fundoplication remains the preferred invasive option for patients with more advanced disease.38
The 2020 ESGE advises against the widespread clinical use of TIF as an alternative to PPI therapy or anti-reflux surgery for GERD because of limited long-term outcome data, inferiority to fundoplication, and modest efficacy in highly selected patients.35 It provides a conditional recommendation supporting TIF in highly selected patients, particularly those with nonerosive reflux disease or mild erosive esophagitis and small or absent hiatal hernia. ESGE notes that TIF improves symptom burden and reduces reliance on acid-suppressive therapy, but emphasizes that objective reductions in esophageal acid exposure are variable and that long-term durability remains less well established than with surgical fundoplication.35
The ASGE, in its most recent guideline update, endorses TIF as a reasonable endoscopic alternative for patients with confirmed GERD who are unwilling or unsuitable for surgical fundoplication and who meet strict anatomical criteria, including a hiatal hernia ≤2 cm and preserved gastroesophageal valve anatomy. The ASGE assigns a conditional recommendation with low-quality evidence, underscoring the importance of appropriate patient selection and shared decision-making.36
Finally, the SAGES-led multisociety consensus statement acknowledges TIF as the most established endoscopic anti-reflux therapy, with evidence demonstrating its superiority over medical therapy for symptom control in selected patients. However, the panel concludes that laparoscopic fundoplication remains the gold standard when feasible, citing greater durability and more consistent control of the objective reflux parameters. TIF is recommended primarily for patients who decline surgery or seek a less-invasive alternative, with the understanding that the long-term outcomes may be inferior to surgical repair (Table 2).37
Compared to earlier iterations, TIF 2.0 incorporates updated device design and standardized procedural criteria aimed at achieving a longer and more circumferential fundoplication, which may contribute to improved reproducibility and clinical outcomes.45 In a recent prospective multicenter cohort study, Canto et al.45 evaluated TIF 2.0 outcomes in patients with objectively confirmed GERD, hiatal hernia <2 cm, and body mass index <35 kg/m² across nine academic and community centers in the United States. A total of 85 patients underwent TIF 2.0, and 81 were included in the final 12-month analysis. Clinical success, defined by improvement in both subjective and objective endpoints, was achieved in 94% of patients, with significant improvements in GERD-HRQL and reflux symptom index scores, a substantial reduction in PPI use, and normalization of AET in 72% of patients undergoing post-procedure pH testing. Notably, acid exposure normalization increased to 94% among patients with an optimized valve configuration (>300° circumference and >3-cm length). The procedure demonstrated a favorable safety profile with no serious device-related adverse events.
TIF has achieved broader acceptance across contemporary GERD guidelines than other endoscopic anti-reflux modalities, although it remains costly and unavailable in most Asian countries.
Endoscopic technologies such as OverStitch for suturing, mucosal ablation, suturing of the EGJ (MASE), GERDx, anti-reflux mucosal plication, and anti-reflux mucosal valvuloplasty are currently under refinement with limited supporting evidence.7,28,29,46
We propose a practical clinical algorithm that integrates diagnostic confirmation, phenotypic classification, and anatomical assessment to guide the selection of endoscopic anti-reflux therapy (Fig. 1). Patients presenting with PPI-refractory or PPI-dependent GERD-like symptoms should first undergo an objective evaluation to confirm or exclude GERD. When a diagnosis of GERD has not been previously established, diagnostic testing off PPI therapy, including upper endoscopy, HRM, and ambulatory reflux monitoring, is recommended. In contrast, patients with previously diagnosed GERD and persistent symptoms should undergo evaluation on PPI therapy to distinguish refractory GERD from overlapping functional or motility disorders.
Only patients with objective evidence of GERD should be considered for invasive anti-reflux intervention. Treatment selection is primarily determined by anatomical factors, particularly the presence or absence of a large hiatal hernia. In patients without a hiatal hernia, endoscopic therapies such as ARMI, TIF, or surgical fundoplication may be considered, whereas those with a hiatal hernia generally require surgical repair with concomitant surgical or endoscopic fundoplication (also known as cTIF). All invasive interventions should be undertaken only after confirming that the patient’s predominant symptoms are attributable to GERD, with careful consideration of the anticipated benefits, potential risks, and individualized clinical context through a shared decision-making process.
Endoscopic anti-reflux therapies provide minimally invasive options for the management of GERD, but should be applied in carefully selected patient groups rather than as routine alternatives to medical or surgical treatment. Accurate diagnosis, objective confirmation of pathological reflux, and careful patient selection within a multidisciplinary framework are essential to optimize outcomes.
Among the currently available modalities, TIF has the most clearly defined role in current guidelines for carefully selected patients with mild-to-moderate disease and minimal anatomical disruption, whereas Stretta is generally confined to a highly restricted, symptom-oriented role. The ARMI is an evolving approach with promising results; however, its use remains limited by the heterogeneity of techniques, lack of robust randomized evidence, and incomplete guideline endorsement.
Importantly, no endoscopic anti-reflux therapy has demonstrated benefits in hard clinical endpoints, including survival and cancer prevention, and data on its long-term durability and cost-effectiveness remain scarce. Future studies incorporating rigorous phenotyping and standardized outcomes are required to better define the role of these therapies in contemporary GERD management.
Fig. 1.
Treatment selection algorithm for invasive anti-reflux therapy in patients with proton pump inhibitor (PPI)-dependent and refractory gastroesophageal reflux disease (GERD). EGD, esophagogastroduodenoscopy; HRM, high-resolution manometry; MII-pH, multichannel intraluminal impedance–pH monitoring; LA, Los Angeles classification; FH, functional heartburn; RH, reflux hypersensitivity; SGB, supragastric belching; ARMI, anti-reflux mucosal intervention; TIF, transoral incisionless fundoplication; cTIF, concomitant TIF.
ce-2026-007f1.jpg
Table 1.
Classification, mechanistic rationale, and technical features of major endoscopic anti-reflux procedures
Category Procedure Mechanism of action Key technical features
Mucosal remodeling (ARMI) ARMS Resection induces cicatrization and scar formation to tighten the cardia and EGJ opening. Involves semi-circumferential mucosal resection using EMR.
ARMA Coagulation induces ulceration and subsequent fibrosis/shrinkage to remodel the EGJ barrier. Uses thermal ablation (e.g., argon plasma coagulation) without tissue resection; technically less demanding than ARMS.
Neuromodulation Stretta Delivers radiofrequency energy to the LES to induce submucosal fibrosis and potentially increase LES pressure and neuromodulation. Uses a balloon catheter with four nitinol needle electrodes.
Endoscopic fundoplication TIF Mechanically reconstructs the GEFV and steepens the Angle of His. Creates full-thickness plications (esophagogastric wrap) secured with polypropylene T-fasteners using the EsophyX device.

ARMI, anti-reflux mucosal intervention; ARMS, anti-reflux mucosectomy; EGJ, esophagogastric junction; EMR, endoscopic mucosal resection; ARMA, anti-reflux mucosal ablation; LES, lower esophageal sphincter; TIF, transoral incisionless fundoplication; GEFV, gastroesophageal flap valve.

Table 2.
Summary of guideline recommendations for endoscopic anti-reflux therapies
Society (year) Transoral incisionless fundoplication Radiofrequency therapy Anti-reflux mucosal interventions
ESGE (2020) Conditional recommendation: advised against widespread use; suggested only for highly selected patients (mild/no esophagitis, small/no hiatal hernia) to reduce PPI use. Conditional recommendation: may be considered for symptom relief in selected patients without erosive esophagitis or hiatal hernia. Suggest against routine use: due to limited data and potential risks, requires more RCTs.
ACG (2022) Conditional recommendation: suggests use for carefully selected patients with proven GERD, regurgitation, and no hiatal hernia >2 cm or severe esophagitis. Cannot recommend: cites inconsistent efficacy, variable outcomes, and limited objective improvement. Not recommended/mentioned: insufficient evidence to support use.
AGA (2022) Consider for routine practice: the only endoscopic procedure with sufficient evidence for selected patients (regurgitation predominant, minimal anatomical disruption). Not recommended: does not include Stretta among recommended options; favors surgical or endoscopic fundoplication. Not recommended: roles are not well-defined or endorsed.
SAGES (2023) Established option: recognized as the most established endoscopic therapy; superior to medical therapy for symptoms but less durable than surgery. Selected patients only: may offer symptomatic benefit but lacks durable objective reflux control; low certainty of evidence. N/A: not explicitly endorsed as a standard option compared to fundoplication.
ASGE (2025) Conditional recommendation: a reasonable alternative for patients with confirmed GERD (HH ≤2 cm) who are unsuitable for or decline surgery. Fallback option: suggested only when surgical or endoscopic fundoplication is not feasible; based on very low-quality evidence. Investigational: use remains limited by technique heterogeneity and lack of robust randomized evidence.

ESGE, European Society of Gastrointestinal Endoscopy; PPI, proton pump inhibitor; RCT, randomized controlled trial; ACG, American College of Gastroenterology; GERD, gastroesophageal reflux disease; AGA, American Gastroenterological Association; SAGES, Society of American Gastrointestinal and Endoscopic Surgeons; ASGE, American Society for Gastrointestinal Endoscopy; HH, hiatal hernia.

  • 1. Katz PO, Dunbar KB, Schnoll-Sussman FH, et al. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2022;117:27–56.ArticlePubMedPMC
  • 2. Hung LJ, Hsu PI, Yang CY, et al. Prevalence of gastroesophageal reflux disease in a general population in Taiwan. J Gastroenterol Hepatol 2011;26:1164–1168.ArticlePubMed
  • 3. Zerbib F, Bredenoord AJ, Fass R, et al. ESNM/ANMS consensus paper: diagnosis and management of refractory gastro-esophageal reflux disease. Neurogastroenterol Motil 2021;33:e14075.ArticlePubMedPDF
  • 4. Spechler SJ, Hunter JG, Jones KM, et al. Randomized trial of medical versus surgical treatment for refractory heartburn. N Engl J Med 2019;381:1513–1523.ArticlePubMed
  • 5. McKinley SK, Dirks RC, Walsh D, et al. Surgical treatment of GERD: systematic review and meta-analysis. Surg Endosc 2021;35:4095–4123.ArticlePubMedPDF
  • 6. Zehetner J, Hoffsten J, Das S, et al. Looking back on a gold standard: a systematic literature review of laparoscopic Nissen fundoplication as an anti-reflux treatment option. Eur Surg 2024;56:143–171.ArticlePDF
  • 7. Kolb JM, Chang KJ. The status of endoscopic therapies for gastroesophageal reflux disease. Curr Opin Gastroenterol 2023;39:326–332.ArticlePubMed
  • 8. Gyawali CP, Yadlapati R, Fass R, et al. Updates to the modern diagnosis of GERD: Lyon consensus 2.0. Gut 2024;73:361–371.ArticlePubMedPMC
  • 9. Jung HK, Tae CH, Song KH, et al. 2020 Seoul consensus on the diagnosis and management of gastroesophageal reflux disease. J Neurogastroenterol Motil 2021;27:453–481.ArticlePubMedPMC
  • 10. Xiao Y, Wu JCY, Lu CL, et al. Clinical practice guidelines for esophageal ambulatory reflux monitoring in Chinese adults. J Gastroenterol Hepatol 2022;37:812–822.ArticlePubMedPDF
  • 11. Davis TA, Gyawali CP. Refractory gastroesophageal reflux disease: diagnosis and management. J Neurogastroenterol Motil 2024;30:17–28.ArticlePubMedPMC
  • 12. Yadlapati R, Kahrilas PJ, Fox MR, et al. Esophageal motility disorders on high-resolution manometry: Chicago classification version 4.0©. Neurogastroenterol Motil 2021;33:e14058.ArticlePubMedPMC
  • 13. Hill LD, Kozarek RA, Kraemer SJ, et al. The gastroesophageal flap valve: in vitro and in vivo observations. Gastrointest Endosc 1996;44:541–547.ArticlePubMed
  • 14. Yeh JH, Lee CT, Hsu MH, et al. Antireflux mucosal intervention (ARMI) procedures for refractory gastroesophageal reflux disease: a systematic review and meta-analysis. Ther Adv Gastroenterol 2022;15:17562848221094959.ArticlePubMedPMCPDF
  • 15. Sumi K, Inoue H, Kobayashi Y, et al. Endoscopic treatment of proton pump inhibitor-refractory gastroesophageal reflux disease with anti-reflux mucosectomy: experience of 109 cases. Dig Endosc 2021;33:347–354.ArticlePubMedPDF
  • 16. Inoue H, Tanabe M, de Santiago ER, et al. Anti-reflux mucosal ablation (ARMA) as a new treatment for gastroesophageal reflux refractory to proton pump inhibitors: a pilot study. Endosc Int Open 2020;8:E133–E138.ArticlePubMedPMC
  • 17. Chou CK, Chen CC, Chen CC, et al. Positive and negative impact of anti-reflux mucosal intervention on gastroesophageal reflux disease. Surg Endosc 2023;37:1060–1069.ArticlePubMedPDF
  • 18. Inoue H, Ito H, Ikeda H, et al. Anti-reflux mucosectomy for gastroesophageal reflux disease in the absence of hiatus hernia: a pilot study. Ann Gastroenterol 2014;27:346–351.PubMedPMC
  • 19. Yoo IK, Ko WJ, Kim HS, et al. Anti-reflux mucosectomy using a cap-assisted endoscopic mucosal resection method for refractory gastroesophageal disease: a prospective feasibility study. Surg Endosc 2020;34:1124–1131.ArticlePubMedPDF
  • 20. Patil G, Dalal A, Maydeo A. Feasibility and outcomes of anti-reflux mucosectomy for proton pump inhibitor dependent gastroesophageal reflux disease: first Indian study (with video). Dig Endosc 2020;32:745–752.ArticlePubMedPDF
  • 21. Deng C, Wu S, Xu F, et al. Underwater antireflux mucosectomy for refractory gastroesophageal reflux disease: a rapid and simple technique for endoscopic treatment. Am J Gastroenterol 2023;118:1735–1736.ArticlePubMed
  • 22. Sumi K, Inoue H, Ando R, et al. Long-term efficacy of antireflux mucosectomy in patients with refractory gastroesophageal reflux disease. Dig Endosc 2024;36:305–313.ArticlePubMed
  • 23. Sui X, Deng C, Wang L, et al. Medium-term clinical efficacy of endoscopic antireflux mucosectomy on laryngopharyngeal reflux: a retrospective multicenter cohort study. Gastrointest Endosc 2023;98:893–900.ArticlePubMed
  • 24. Lee YS, Kim JH, Yon DK, et al. Short and long term effect of anti-reflux mucosectomy with cap-assisted endoscopic mucosal resection for refractory gastroesophageal disease. Surg Endosc 2024;38:2180–2187.ArticlePubMedPDF
  • 25. Lee AY, Choi JW, Heo JH, et al. The comparative study of Stretta radiofrequency and anti-reflux mucosectomy in the management of intractable gastroesophageal reflux disease: a single-center retrospective study from Korea. Clin Endosc 2025;58:409–417.ArticlePubMedPMCPDF
  • 26. Lee AY, Kim SH, Cho JY. Comparative evaluation of endoscopic anti-reflux mucosectomy and stretta radiofrequency ablation in the management of gastroesophageal reflux disease: insights from a retrospective multicenter cohort study. Surg Endosc 2024;38:4278–4286.ArticlePubMedPDF
  • 27. Yamamoto K, Inoue H, Tanaka I, et al. A pilot study on anti-reflux mucoplasty with valve as novel endoscopic therapy for gastroesophageal reflux disease. DEN Open 2026;6:e70131.ArticlePubMed
  • 28. Inoue H, Yamamoto K, Shimamura Y, et al. Pilot study on anti-reflux mucoplasty: advancing endoscopic anti-reflux therapy for gastroesophageal reflux disease. Dig Endosc 2024;36:690–698.ArticlePubMed
  • 29. Lu J, Chen F, Lv X, et al. Endoscopic construction of an antireflux mucosal barrier for the treatment of GERD: a pilot study (with video). Gastrointest Endosc 2023;98:1017–1022.ArticlePubMed
  • 30. Lee AY, Kim SH, Cho JY. Comparative clinical feasibility of antireflux mucosectomy and antireflux mucosal ablation in the management of gastroesophageal reflux disease: retrospective cohort study. Dig Endosc 2024;36:1328–1337.ArticlePubMed
  • 31. Chavan D, Koduri KK, Singh AP, et al. Role of antireflux mucosal ablation in "reflux-predominant" refractory gastroesophageal reflux disease: a randomized sham-controlled trial. Endoscopy 2026 Jan 9 [Epub]. https://doi.org/10.1055/a-2740-9297Article
  • 32. Shimamura Y, Inoue H, Tanabe M, et al. Clinical outcomes of anti-reflux mucosal ablation for gastroesophageal reflux disease: an international bi-institutional study. J Gastroenterol Hepatol 2024;39:149–156.ArticlePubMed
  • 33. Hernández Mondragón OV, Zamarripa Mottú RA, García Contreras LF, et al. Clinical feasibility of a new antireflux ablation therapy on gastroesophageal reflux disease (with video). Gastrointest Endosc 2020;92:1190–1201.ArticlePubMed
  • 34. Chen CC, Chou CK, Yuan MC, et al. Effect of anti-reflux mucosal ablation on esophageal motility in patients with gastroesophageal reflux disease: a study based on high-resolution impedance manometry. J Neurogastroenterol Motil 2025;31:75–85.ArticlePubMedPMC
  • 35. Weusten BLAM, Barret M, Bredenoord AJ, et al. Endoscopic management of gastrointestinal motility disorders-part 2: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2020;52:600–614.ArticlePubMed
  • 36. Desai M, Ruan W, Thosani NC, et al. American Society for Gastrointestinal Endoscopy guideline on the diagnosis and management of GERD: summary and recommendations. Gastrointest Endosc 2025;101:267–284.ArticlePubMed
  • 37. Slater BJ, Collings A, Dirks R, et al. Multi-society consensus conference and guideline on the treatment of gastroesophageal reflux disease (GERD). Surg Endosc 2023;37:781–806.ArticlePubMed
  • 38. Yadlapati R, Gyawali CP, Pandolfino JE. AGA clinical practice update on the personalized approach to the evaluation and management of GERD: expert review. Clin Gastroenterol Hepatol 2022;20:984–994.ArticlePubMedPMC
  • 39. Fass R, Cahn F, Scotti DJ, et al. Systematic review and meta-analysis of controlled and prospective cohort efficacy studies of endoscopic radiofrequency for treatment of gastroesophageal reflux disease. Surg Endosc 2017;31:4865–4882.ArticlePubMedPDF
  • 40. Lipka S, Kumar A, Richter JE. No evidence for efficacy of radiofrequency ablation for treatment of gastroesophageal reflux disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2015;13:1058–1067.ArticlePubMed
  • 41. Zerbib F, Sacher-Huvelin S, Coron E, et al. Randomised clinical trial: oesophageal radiofrequency energy delivery versus sham for PPI-refractory heartburn. Aliment Pharmacol Ther 2020;52:637–645.ArticlePubMedPDF
  • 42. Huang X, Chen S, Zhao H, et al. Efficacy of transoral incisionless fundoplication (TIF) for the treatment of GERD: a systematic review with meta-analysis. Surg Endosc 2017;31:1032–1044.ArticlePubMedPDF
  • 43. McCarty TR, Itidiare M, Njei B, et al. Efficacy of transoral incisionless fundoplication for refractory gastroesophageal reflux disease: a systematic review and meta-analysis. Endoscopy 2018;50:708–725.ArticlePubMed
  • 44. Testoni S, Hassan C, Mazzoleni G, et al. Long-term outcomes of transoral incisionless fundoplication for gastro-esophageal reflux disease: systematic-review and meta-analysis. Endosc Int Open 2021;9:E239–E246.ArticlePubMedPMC
  • 45. Canto MI, Diehl DL, Parker B, et al. Outcomes of transoral incisionless fundoplication (TIF 2.0): a prospective multicenter cohort study in academic and community gastroenterology and surgery practices (with video). Gastrointest Endosc 2025;101:90–102.ArticlePubMed
  • 46. Kalapala R, Karyampudi A, Nabi Z, et al. Endoscopic full-thickness plication for the treatment of PPI-dependent GERD: results from a randomised, sham controlled trial. Gut 2022;71:686–694.ArticlePubMed

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  

      • Cite
        CITE
        export Copy Download
        Close
        Download Citation
        Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

        Format:
        • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
        • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
        Include:
        • Citation for the content below
        Endoscopic anti-reflux treatment for gastroesophageal reflux disease
        Close
      • XML DownloadXML Download
      Figure
      • 0
      Related articles
      Endoscopic anti-reflux treatment for gastroesophageal reflux disease
      Image
      Fig. 1. Treatment selection algorithm for invasive anti-reflux therapy in patients with proton pump inhibitor (PPI)-dependent and refractory gastroesophageal reflux disease (GERD). EGD, esophagogastroduodenoscopy; HRM, high-resolution manometry; MII-pH, multichannel intraluminal impedance–pH monitoring; LA, Los Angeles classification; FH, functional heartburn; RH, reflux hypersensitivity; SGB, supragastric belching; ARMI, anti-reflux mucosal intervention; TIF, transoral incisionless fundoplication; cTIF, concomitant TIF.
      Endoscopic anti-reflux treatment for gastroesophageal reflux disease
      Category Procedure Mechanism of action Key technical features
      Mucosal remodeling (ARMI) ARMS Resection induces cicatrization and scar formation to tighten the cardia and EGJ opening. Involves semi-circumferential mucosal resection using EMR.
      ARMA Coagulation induces ulceration and subsequent fibrosis/shrinkage to remodel the EGJ barrier. Uses thermal ablation (e.g., argon plasma coagulation) without tissue resection; technically less demanding than ARMS.
      Neuromodulation Stretta Delivers radiofrequency energy to the LES to induce submucosal fibrosis and potentially increase LES pressure and neuromodulation. Uses a balloon catheter with four nitinol needle electrodes.
      Endoscopic fundoplication TIF Mechanically reconstructs the GEFV and steepens the Angle of His. Creates full-thickness plications (esophagogastric wrap) secured with polypropylene T-fasteners using the EsophyX device.
      Society (year) Transoral incisionless fundoplication Radiofrequency therapy Anti-reflux mucosal interventions
      ESGE (2020) Conditional recommendation: advised against widespread use; suggested only for highly selected patients (mild/no esophagitis, small/no hiatal hernia) to reduce PPI use. Conditional recommendation: may be considered for symptom relief in selected patients without erosive esophagitis or hiatal hernia. Suggest against routine use: due to limited data and potential risks, requires more RCTs.
      ACG (2022) Conditional recommendation: suggests use for carefully selected patients with proven GERD, regurgitation, and no hiatal hernia >2 cm or severe esophagitis. Cannot recommend: cites inconsistent efficacy, variable outcomes, and limited objective improvement. Not recommended/mentioned: insufficient evidence to support use.
      AGA (2022) Consider for routine practice: the only endoscopic procedure with sufficient evidence for selected patients (regurgitation predominant, minimal anatomical disruption). Not recommended: does not include Stretta among recommended options; favors surgical or endoscopic fundoplication. Not recommended: roles are not well-defined or endorsed.
      SAGES (2023) Established option: recognized as the most established endoscopic therapy; superior to medical therapy for symptoms but less durable than surgery. Selected patients only: may offer symptomatic benefit but lacks durable objective reflux control; low certainty of evidence. N/A: not explicitly endorsed as a standard option compared to fundoplication.
      ASGE (2025) Conditional recommendation: a reasonable alternative for patients with confirmed GERD (HH ≤2 cm) who are unsuitable for or decline surgery. Fallback option: suggested only when surgical or endoscopic fundoplication is not feasible; based on very low-quality evidence. Investigational: use remains limited by technique heterogeneity and lack of robust randomized evidence.
      Table 1. Classification, mechanistic rationale, and technical features of major endoscopic anti-reflux procedures

      ARMI, anti-reflux mucosal intervention; ARMS, anti-reflux mucosectomy; EGJ, esophagogastric junction; EMR, endoscopic mucosal resection; ARMA, anti-reflux mucosal ablation; LES, lower esophageal sphincter; TIF, transoral incisionless fundoplication; GEFV, gastroesophageal flap valve.

      Table 2. Summary of guideline recommendations for endoscopic anti-reflux therapies

      ESGE, European Society of Gastrointestinal Endoscopy; PPI, proton pump inhibitor; RCT, randomized controlled trial; ACG, American College of Gastroenterology; GERD, gastroesophageal reflux disease; AGA, American Gastroenterological Association; SAGES, Society of American Gastrointestinal and Endoscopic Surgeons; ASGE, American Society for Gastrointestinal Endoscopy; HH, hiatal hernia.


      Clin Endosc : Clinical Endoscopy Twitter Facebook
      Close layer
      TOP